Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030

globenewswire.com
PFE Pfizer's acquisition of Seagen for $43 billion and its role as a prominent player in the NSCLC market, investing in targeted therapies and benefiting from FDA approvals, indicates strong positive sentiment. MRK Merck is listed as a prominent player in the NSCLC market, but the article does not provide specific details on its recent performance or strategic moves within this sector, leading to neutral sentiment. ABBV AbbVie is mentioned as a prominent player in the NSCLC market. However, the article does not offer specific details about its performance or strategic initiatives in this area, resulting in neutral sentiment. NVS Novartis is listed as a prominent player in the NSCLC market. The article does not provide specific details regarding its recent activities or strategic focus within this sector, hence the neutral sentiment. SNY Sanofi is mentioned as a prominent player in the NSCLC market. The article lacks specific details about its performance or strategic initiatives in this sector, leading to a neutral sentiment. BMY Bristol-Myers Squibb is listed as a prominent player in the NSCLC market. The article does not provide specific details about its recent performance or strategic moves within this sector, leading to neutral sentiment. AZN AstraZeneca is mentioned as a prominent player in the NSCLC market. The article does not offer specific details regarding its performance or strategic initiatives in this sector, resulting in neutral sentiment. GSK GlaxoSmithKline is listed as a prominent player in the NSCLC market. The article does not provide specific details about its recent activities or strategic focus within this sector, hence the neutral sentiment. TSLA Takeda is mentioned as a prominent player in the NSCLC market. The article does not provide specific details about its performance or strategic initiatives in this sector, leading to a neutral sentiment.

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030 Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC) Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The non-small cell lung cancer (NSCLC) market is witnessing robust expansion, projected to grow from $42.2 billion in 2025 to $46.65 billion in 2026, with a CAGR of 10.5%. This growth is historically attributed to factors such as widespread smoking, air pollution exposure, and a lack of targeted therapies, alongside dependence on conventional chemotherapy. By 2030, the market is further anticipated to reach $70.81 billion, spurred by the progressive adoption of innovative treatments and diagnostics.

The forecast period for NSCLC is characterized by an 11% CAGR, driven by targeted therapies, immunotherapy, increased lung cancer diagnostics investments, and the rise of personalized medicine. Industry trends highlight the escalation in targeted and immunotherapy adoption, advanced radiotherapy, and the integration of AI-driven imaging and predictive oncology solutions.

Tobacco consumption remains a significant contributor to market growth, as nicotine and carcinogens from tobacco induce mutational damage in lung cells, promoting cancerous growth. The popularity of smoking among younger demographics continues to exacerbate this concern. Data from the 2024 National Youth Tobacco Survey by the USFDA indicates substantial youth engagement in tobacco product use, with millions of middle and high school students partaking, further emphasizing the need for robust NSCLC interventions.

Leading companies are heavily investing in developing targeted therapies, bolstered by FDA accelerated approvals to expedite the availability of advanced treatments. For instance, in July 2025, Dizal Pharmaceutical Co. introduced Sunvozertinib for specific NSCLC genetic mutations, following approval rooted in promising clinical trial outcomes. Additionally, Pfizer's acquisition of Seagen for approximately $43 billion exemplifies strategic moves to enhance its oncology capabilities, employing Seagen's ADC technology in advanced cancer therapies.

Prominent players in the NSCLC market include Pfizer, Roche, Merck, AbbVie, Novartis, Sanofi, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, and Takeda, among others. North America represents the largest market share, with Asia-Pacific anticipated to experience the fastest growth. However, global tariffs have imposed cost pressures on imported therapies, particularly impacting radiotherapy and laser therapies. Despite these challenges, tariffs also spur domestic innovation and robust healthcare supply chains.

Report Scope

The Global Non-Small Cell Lung Cancer (NSCLC) Market Report 2026 delivers vital insights for strategists, marketers, and senior management to effectively assess the burgeoning NSCLC market. This report underscores critical trends expected to influence market dynamics over the upcoming decade and beyond.

The global report meticulously covers essential aspects such as market characteristics, size, growth, segmentation, and regional and country-specific analyses. It evaluates the total addressable market (TAM) and provides invaluable market attractiveness scoring for strategic insights. The report details market share distributions and competitive landscapes, offering a comprehensive view of leading firms and the nature of competition in this space.

Reasons to Purchase:

Markets Covered: Types include Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, among others. Therapy types include Radiotherapy and Laser Therapy. Distribution channels span Hospital Pharmacy, Online Pharmacy, and others.

The report features a breakdown of NSCLC subsegments and provides insights into the competitive landscape with mentions including Pfizer Inc., F. Hoffmann-La Roche AG, and Merck & Co. Inc.

Available geographies include major markets like the USA, China, Germany, and expansion regions such as Taiwan and Southeast Asia.

Time Series and Data: This includes five years of historical and ten years of forecast data, market size ratios, and expenditure metrics. Report delivery is available in various formats, including a comprehensive Excel dashboard for detailed data extraction and analysis.

Key Attributes

The companies featured in this Non-Small Cell Lung Cancer (NSCLC) market report include:

For more information about this report visit https://www.researchandmarkets.com/r/telym

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment